Concepedia

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer

Randall Rago, Albert Einstein, Richard M. Lush, Tomasz M. Beer, Yoo-Joung Ko, W. David Henner, Glenn J. Bubley, Elizabeth Merica, Varun Garg, Ene Ette,

Cancer Chemotherapy and Pharmacology · 2003 · 32 citations · 33 references

DOI

Concepts

References

33

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

, , +10

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

I. F. Tannock, David Osoba, Martin R. Stockler et al. · Journal of Clinical Oncology · 1996 · 1.6K citations

, , +17

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Glenn J. Bubley, Michael A. Carducci, William L. Dahut et al. · Journal of Clinical Oncology · 1999 · 984 citations

, , +16

Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells

Preet M. Chaudhary, Igor B. Roninson · Cell · 1991 · 957 citations

, , +11

Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

Philip W. Kantoff, Susan Halabi, Mark R. Conaway et al. · Journal of Clinical Oncology · 1999 · 893 citations

, , +11